- Home
- OCFC vs GYRE Comparison
OCFC vs GYRE Comparison
Compare OCFC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- GYRE
- Stock Information
- Founded
- OCFC 1902
- GYRE 2002
- Country
- OCFC United States
- GYRE United States
- Employees
- OCFC N/A
- GYRE N/A
- Industry
- OCFC Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- GYRE Health Care
- Exchange
- OCFC Nasdaq
- GYRE Nasdaq
- Market Cap
- OCFC 944.6M
- GYRE 897.1M
- IPO Year
- OCFC 1996
- GYRE N/A
- Fundamental
- Price
- OCFC $18.39
- GYRE $7.74
- Analyst Decision
- OCFC Buy
- GYRE Strong Buy
- Analyst Count
- OCFC 4
- GYRE 1
- Target Price
- OCFC $21.25
- GYRE $18.00
- AVG Volume (30 Days)
- OCFC 282.9K
- GYRE 85.6K
- Earning Date
- OCFC 10-16-2025
- GYRE 08-11-2025
- Dividend Yield
- OCFC 4.34%
- GYRE N/A
- EPS Growth
- OCFC N/A
- GYRE N/A
- EPS
- OCFC 1.41
- GYRE 0.02
- Revenue
- OCFC $376,075,000.00
- GYRE $102,189,000.00
- Revenue This Year
- OCFC N/A
- GYRE $21.04
- Revenue Next Year
- OCFC $13.22
- GYRE $89.64
- P/E Ratio
- OCFC $13.08
- GYRE $455.91
- Revenue Growth
- OCFC 0.00
- GYRE N/A
- 52 Week Low
- OCFC $14.29
- GYRE $6.11
- 52 Week High
- OCFC $21.87
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- OCFC 62.38
- GYRE 49.96
- Support Level
- OCFC $18.07
- GYRE $7.61
- Resistance Level
- OCFC $18.75
- GYRE $8.40
- Average True Range (ATR)
- OCFC 0.53
- GYRE 0.53
- MACD
- OCFC 0.18
- GYRE 0.04
- Stochastic Oscillator
- OCFC 85.00
- GYRE 62.92
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.